Search research articles
Contact Us
Filters
Showing results (251-260 of 311) with videos related to
Page
of 32
Sort By:
Cancers
|
July 27, 2024
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> 2020, <i>12</i>, 512
Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Liver Cancer
|
August 11, 2022
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
James J Harding, Ahmad Awada, Gael Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer
Sara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2021
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer
Sara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
NPJ Breast Cancer
|
September 22, 2021
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
Andrea Gombos, David Venet, Lieveke Ameye, et al.
NPJ Breast Cancer
|
March 17, 2022
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
Andrea Gombos, David Venet, Lieveke Ameye, et al.
Cancer Chemotherapy and Pharmacology
|
October 12, 2012
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
Bojana Milojkovic Kerklaan, Bojana Milojkovic Kerklaan, Veronique Diéras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 10, 2024
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer
Eric Van Cutsem, Joelle Collignon, Rikke L Eefsen, et al.
Investigational New Drugs
|
August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Rebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Vivek Subbiah, Irene Braña, Alessandra Longhi, et al.
Page
of 32
Search research articles
Search
Showing results (251-260 of 311) with videos related to
Sort By:
Page
of 32
Cancers
|
July 27, 2024
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> 2020, <i>12</i>, 512
Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Liver Cancer
|
August 11, 2022
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers
James J Harding, Ahmad Awada, Gael Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer
Sara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2021
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer
Sara M Tolaney, Solmaz Sahebjam, Emilie Le Rhun, et al.
NPJ Breast Cancer
|
September 22, 2021
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
Andrea Gombos, David Venet, Lieveke Ameye, et al.
NPJ Breast Cancer
|
March 17, 2022
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
Andrea Gombos, David Venet, Lieveke Ameye, et al.
Cancer Chemotherapy and Pharmacology
|
October 12, 2012
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
Bojana Milojkovic Kerklaan, Bojana Milojkovic Kerklaan, Veronique Diéras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 10, 2024
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer
Eric Van Cutsem, Joelle Collignon, Rikke L Eefsen, et al.
Investigational New Drugs
|
August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Rebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Vivek Subbiah, Irene Braña, Alessandra Longhi, et al.
Page
of 32